Clinical trials: Neoplasm, Experimental
Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
- Trial name
- NCT03351231
- Testing
- BMS-986242, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms Malignant
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
- Trial name
- NCT01121588
- Testing
- Crizotinib
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 44 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer.
- Trial name
- HNC (NCT03998696)
- Testing
- Cisplatin 40 mg/m2, Cisplatin 100 mg/m2
- Where
- Bangladesh
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.
- Trial name
- NCT03363776
- Testing
- BMS-986277, Nivolumab
- Where
- 3 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04134208
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT01592370
- Testing
- Nivolumab, Ipilimumab, Lirilumab
- Where
- 43 sites in United States, Belgium and 4 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Pediatric ALL, Relapsed Pediatric ALL
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
- Conditions
- Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
- Trial name
- NCT00439296
- Testing
- ABT-751, Dexamethasone, PEG-asparaginase
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Malignant Solid Tumor
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
- Trial name
- NCT02754141
- Testing
- BMS-986179, Nivolumab, rHuPH20
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 235 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers…
- Trial name
- NCT02737475
- Testing
- BMS-986178, Nivolumab, Ipilimumab
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 166 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Cervical Intraepithelial Neoplasia
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
- Trial name
- NCT05496231
- Testing
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation
- Where
- 68 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.
- Trial name
- NCT00960440
- Testing
- CP-690,550
- Where
- 92 sites in United States, Australia and 12 more
- Volunteers
- 399 people
- Sponsor
- Pfizer
Breast Cancer
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions…
- Trial name
- PRART (NCT04175210)
- Testing
- Radiation therapy - 3 weeks, Radiation therapy - 2 weeks
- Where
- 3 sites in United States
- Volunteers
- 397 people
- Sponsor
- Weill Medical College of Cornell University
Condylomata Acuminata
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence…
- Trial name
- NCT00090285
- Testing
- (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan.
- Trial name
- NCT01347866
- Testing
- PF-05212384, PD-0325901, irinotecan
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Advanced Solid Tumors
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize).
- Trial name
- NCT00557856
- Testing
- PF-03446962
- Where
- 10 sites in United States, Italy and 1 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
- Trial name
- NCT03994601
- Testing
- BMS-986288, Nivolumab, Regorafenib
- Where
- 40 sites in United States, Argentina and 5 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb